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Abstract 
Many 3D in vitro models induce breast cancer spheroid formation; however, this alone does not 
recapitulate the complex in vivo phenotype. To effectively screen therapeutics, we urgently need 
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to validate in vitro cancer spheroid models against the gold standard of xenografts. We designed a 
new oxime-crosslinked hyaluronan (HA) hydrogel, manipulating gelation rate and mechanical 
properties to grow breast cancer spheroids in 3D. Our HA-oxime breast cancer model maintains 
the gene expression profile most similar to that of tumour xenografts based on a pan-cancer gene 
expression profile (comprising 730 genes) of 3 different human breast cancer subtypes compared 
to Matrigel or conventional 2D culture. Differences in gene expression between breast cancer 
cultures in HA-oxime versus Matrigel or 2D were confirmed for 12 canonical pathways by gene 
set variation analysis. Importantly, drug response was dependent on the culture method. Breast 
cancer cells responded better to the Rac inhibitor (EHT-1864) and the PI3K inhibitor (AZD6482) 
when cultured in HA-oxime versus Matrigel. This study demonstrates, for the first time, the 
superiority of an HA-based hydrogel as a platform for in vitro breast cancer culture of both 
primary, patient-derived cells and cell lines, and provides a hydrogel culture model that closely 
matches that in vivo. 
Main 
Despite improvements in initial target identification using computational approaches,[1] 
and several proposed hydrogels to culture cells for the in vitro stage of drug discovery,[2] two-
dimensional (2D) culture on tissue culture poly(styrene) (TCPS) continues to be used to screen 
cancer therapeutics. 2D culture does not represent the in vivo microenvironment either 
mechanically or biochemically, thereby leading to false positive (and likely false negative) drug 
hits.[3]  In vivo xenograft tumour models recapitulate human disease more faithfully, but are costly, 
time-consuming and complicated by the use of immunocompromised mice.[4] The inaccurate but 
rapid and simple method of testing drugs in 2D coupled with the complexity of xenograft models, 
has motivated the development of more representative three-dimensional (3D) culture platforms. 
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A suitable 3D culture system must be sufficiently stable for drug screening and benchmarked 
against gold standard in vivo xenograft tumour models.[5] The limited availability of such 3D 
models results in the continued reliance on 2D culture, even with the recognition that 2D culture 
does not accurately predict in vivo outcomes.  
Unlike 2D culture, where breast epithelial cancer cells form a monolayer, 3D models of 
cancer recapitulate many disease characteristics such as formation of cancer spheroids with tight 
junctions, and inclusion of key biochemical and mechanical cues of the native extracellular matrix 
(ECM).[6] Typically, cancer spheroids are formed by growing epithelial cancer cells in 3D using 
non-adherent conditions. This method is rapid and provides remarkable control of the spheroid 
size;[7] yet, unsurprisingly, the gene expression profiles of these cancer spheroids (CS) formed by 
aggregation resemble cells cultured in 2D more closely than those of xenograft tumours.[8] 
Therefore, spheroid formation alone does not recapitulate the in vivo microenvironment.[9] Non-
adherent conditions lack critical ECM components, which both affect cell function through 
integrin-mediated signaling pathways, such as β1, and influence drug effectiveness.[10]  
Laminin-rich extracellular matrices, such as Matrigel®, which is derived from the 
Engelbreth-Holm-Swarm murine sarcoma, are favored for 3D cell culture as they contain some 
physiologically relevant ECM proteins that mimic the breast tumour microenvironment.[11]  
However, Matrigel is ill-defined,[12] and its composition, physicochemical and biomechanical 
properties have limited tunability.[13] Moreover, Matrigel does not include key matrix components 
found in the breast cancer microenvironment such as hyaluronan (HA), which is produced by 
tumour and stromal cells and is linked to disease progression.[14] The diversity of cell-surface 
integrin expression and tumour microenvironment properties across breast cancer subtypes require 
a model that is tunable to meet these complexities.[15] 
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The majority of chemically crosslinked hydrogels utilize chemistries that have rapid 
reaction kinetics,[16] such as the thiol-Michael addition ligation,[17] and limit uniform cell 
encapsulation, making reproducible in vitro cell culture challenging. Moreover, many scaffold 
components need to be stored under inert gas due to air-sensitive functional groups, such as thiols, 
and/or require external stimuli to promote crosslinking, which complicates scale up.[18, 19] To 
achieve a more controlled system for cell encapsulation, we combined fast-reacting HA-aldehyde 
and slow-reacting HA-ketone with poly(ethylene glycol) (PEG)-oxyamine to create defined 3D 
hydrogels via oxime click chemistry. Oxime ligation is hydrolytically stable, thereby allowing 
long-term encapsulation of breast cancer cells – a key advance over current strategies that are 
inherently limited by reversible reactions of hydrazone or Diels-Alder chemistries for 
crosslinking.[20, 21] In addition, the oxime chemistry is insensitive to oxidation, facile to use and 
enables controlled gelation rates, which is typically not possible with other click chemistry 
reactions.[18] We used these newly synthesized oxime-crosslinked HA hydrogels to benchmark the 
gene expression of breast cancer cells against tumour xenografts grown in mice and evaluate drug 
response in comparison with conventional culture in Matrigel and 2D TCPS (Fig. 1a). 
Synthesis of HA-oxime Hydrogels 
We synthesized HA-oxime gels with HA-ketone (HAK), HA-aldehyde (HAA) and PEG-
oxyamine, each component of which first needed to be synthesized. HAK was synthesized, for the 
first time, in a two-step reaction: (1) amide coupling of 3-(2-methyl-1,3-dioxolan-2-yl)propan-1-
amine with 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (DMTMM) as 
an activator and (2) acid-catalyzed ketone deprotection (Fig. 1b). We found the substitution of 
ketone to be tunable between 28 ± 3% and 55 ± 2% by increasing the equivalents of DMTMM 
from 1.0 to 2.5, respectively (Fig. S1). We chose to use HAK with approximately 40% ketone 
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substitution to produce hydrogels because it was water soluble and easy to handle. Similarly, we 
synthesized aldehyde-modified HA (HAA) in two steps: (1) amidation of carboxylic acid groups 
on HA with DMTMM/aminoacetaldehyde dimethyl acetal, and (2) deprotection of the resulting 
HA-acetal with aqueous acid (Fig. 1c, Fig S2). The PEG-substituted oxyamine crosslinker was 
prepared from either 4-arm PEG-tetramine or 2-arm PEG-bisamine and (boc-aminooxy)acetic acid 
with carbodiimide coupling followed by acid-catalyzed deprotection to yield PEGOA4 and 
PEGOA2, respectively (Fig. S2). 
We combined HAK and HAA with PEGOA4 and laminin (a common extracellular matrix 
protein) to produce crosslinked hydrogels with tunable biochemical properties to grow breast 
cancer spheroids (Fig. 1d). To show that both HAK and HAA biopolymers were crosslinked with 
PEG-oxyamine, we compared the stability of hydrogels comprised of equal weight percent of 
either HAK/HAA or unmodified-HA/HAA crosslinked with PEG-oxyamine: HAK/HAA 
hydrogels remained stable over at least 28 days (with less than 5% decrease in mass) whereas gels 
formed from HA/HAA slowly dissociated, losing 50 ± 2% of their mass between day 1 and 28, 
reflecting the dissolution of uncrosslinked HA (Fig. S3). Gels crosslinked with four-armed 
PEGOA4 swelled significantly less than those crosslinked with bifunctional PEGOA2 (Fig. S3). 
Although both remained intact over four weeks, we used PEGOA4 in all subsequent experiments 
because the increased swelling of PEGOA2  crosslinked gels would alter hydrogel mechanical 
properties and hence cell phenotype.[22]   
Tunable Gelation of HA-oxime Hydrogels Influences 3D Cell Distribution 
To achieve uniform 3D cell distribution, hydrogels must form rapidly enough to avoid cell 
aggregation due to gravity during gelation, but slow enough for practical use. HAA only 
crosslinked hydrogels (0:1 HAK:HAA) formed too quickly for cell encapsulation, requiring cells 
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to be cultured on top of those gels versus within.[21] In contrast, hydrogels synthesized with only 
HAK (1:0, HAK:HAA) and PEGOA4 formed too slowly, with gelation at 87 ± 11 min. 
Consequently, when single breast cancer cells were encapsulated in HAK-only HA-oxime gels, 
cells accumulated in the bottom of the well, due to the slow crosslinking reaction between ketones 
and oxyamines (Fig. 1e). We used rheology to characterize the gelation rate of HA-oxime 
hydrogels with varying HAK:HAA mass ratios (Fig. S4). The gelation rate increased significantly 
with an increasing amount of HAA (Fig. 1f). HA-oxime hydrogels produced with HAK:HAA mass 
ratios of either 7:1 or 3:1, at a constant oxyamine to ketone/aldehyde mole ratio of 0.60, resulted 
in mean gelation times of 35 and 25 min, respectively. At higher weight percentages of the faster 
gelling HAA (HAK:HAA of 1:1), the resulting crosslinked gel formed too rapidly for 
quantification by rheology. We used HAK:HAA of 3:1 in subsequent assays and found a uniform 
distribution of viable cells (Fig. S5). This uniform distribution was maintained for a longer time 
when cells were grown in HA-oxime hydrogels versus those in Matrigel or a commercially 
available HA-based hydrogel, HyStem-C (HA-thiol/gelatin-thiol crosslinked with PEG diacrylate) 
(Fig. S5c). 
Composition-controlled Mechanical Properties and Enzyme-specific Degradation of HA-
oxime Hydrogels 
We were interested in understanding the mechanical tunability of HA-oxime hydrogels in 
relation to Matrigel, the current standard for 3D cell and organoid culture. Matrigel compositions, 
purchased with protein concentrations of 8.50 and 18.43 mg·mL-1, had compressive moduli of 0.9 
± 0.7 kPa and 1.6 ± 0.4 kPa, respectively, which were not significantly different from each other 
(Fig. 1g). These formulations are typically used for in vitro culture and underscore the limited 
mechanical tunability offered by Matrigel.[23] In contrast, the stiffness of HA-oxime hydrogels 
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varied with the ratio of HAK to HAA. HA-oxime hydrogels are highly tunable over 2 orders of 
magnitude, between 0.3 and 15 kPa, by either varying the crosslinking density or the weight 
percent of HA (Fig. S6). This range covers the stiffness reported for mouse mammary tumours 
(~1.5-4.0 kPa), and human breast cancer tissue (~5-16 kPa), as measured by compression and 
atomic force microscopy, respectively.[24, 25]  
HAK-only (1.35 wt%) hydrogels were significantly stiffer (15 ± 1 kPa) than HAA-only 
(1.35 wt%) hydrogels (5.5 ± 0.4 kPa) at a constant mole ratio (0.80) of oxyamine to 
ketone/aldehyde (Fig. S6). We attributed this difference in modulus of HAK-oxime and HAA-
oxime hydrogels to the difference in molar mass. While we started with the same molar mass of 
HA, synthesis of HAK resulted in a molar mass of 311 kg·mol-1 whereas that of HAA resulted in 
a molar mass of 122 kg·mol-1 as measured by gel permeation chromatography. Importantly, there 
was no change in oxyamine to oxime conversion with all HAK and HAA formulations, as 
quantified by 1H NMR spectroscopy (Fig. S7), further indicating that the molar mass difference 
accounted for the difference in compressive modulus. The stiffness of gel formulations with 3:1 
and 1:1 HAK:HAA weight ratios were not statistically different from Matrigel, so we used 3:1 
ratio for future experiments as it was easier to handle. We found that these HA-oxime gels were 
stable for 28 days when swollen in PBS or when treated with collagenase and degraded only in the 
presence of hyaluronidase, highlighting the enzyme-specific degradability (Fig. 1h). Importantly, 
breast cancer cells are known to produce hyaluronidase, which allows dynamic, cell-based 
spatiotemporal remodeling of the HA-oxime hydrogels during cell growth.[26] 
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Figure 1. Synthesis and characterization of the HA-oxime hydrogel to model breast cancer in vitro. 
(a) The overall goal was to benchmark the gene expression profile of cells cultured in vitro in our 
novel HA-oxime hydrogels relative to conventional culture in either Matrigel or 2D tissue culture 
polystyrene (TCPS) to those cells grown in vivo. This methodology allows us to identify pathways 
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that can then be targeted in drug screening assays.  (b) Synthesis of HA-ketone using DMTMM 
coupling to HA with 3-(2-methyl-1,3-dioxolan-2-yl)propan-1-amine followed by acid-catalyzed 
deprotection, and neutralization. (c) Synthesis of HA-aldehyde using DMTMM coupling with 
aminoacetaldehyde dimethyl acetal followed by acid-catalyzed deprotection, and neutralization. 
(d) HA-oxime crosslinked hydrogels comprised of HA-ketone (HAK, red), HA-aldehyde (HAA, 
blue), and poly(ethylene glycol)-tetraoxyamine (PEGOA4, orange) and formed in the presence of 
laminin (green) and breast cancer cells (tan), which resulted in uniformly distributed cells. (e) 
Distribution of encapsulated MDA-MB-468 cells after 24 h in HA-oxime hydrogels: in HAK 
crosslinked gels, cells aggregate at the bottom of the well due to the slow gelation whereas in 
HAK:HAA (3:1 mass ratio), cells are evenly distributed. Cells were stained for viability with 
calcein AM (live, green) and ethidium homodimer-1 (dead, red); scale bar represents 200 μm (n = 
3 independent experiments; mean + s.d. plotted, ***p<0.001, one-way ANOVA, Tukey’s post-
hoc test). (f) Gelation time of HA-oxime hydrogels crosslinked with PEGOA4 (n = 3, mean + s.d., 
***p<0.001, one-way ANOVA, Tukey’s post-hoc test). (g) Compressive modulus of HA-oxime 
hydrogels compared to growth factor reduced Matrigel (n = 4, mean + s.d. plotted, *p<0.05; 
**p<0.01, one-way ANOVA, Tukey’s post-hoc test). The red shaded area represents the range in 
stiffness of mouse tumours reported in the literature.[24] (h) HA-oxime hydrogel prepared from 3:1 
HA-ketone (0.90 wt%) and HA-aldehyde (0.30 wt%) crosslinked with PEGOA4 (1.04 wt%) was 
stable over 28 days at 37 °C in Hank's balanced salt solution (HBSS) and in the presence of 
collagenase, but degraded in the presence of hyaluronidase. The percent of remaining hydrogel 
was determined from the mass measurements (n = 3, mean + s.d. plotted). 
Biochemically-tuned Laminin-containing HA-oxime Hydrogels Interact with Cells 
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To mimic the heterogeneity of the extracellular matrix in breast cancer and enhance cell 
interaction with the HA-oxime hydrogels,[27] we mixed laminin-1 (Ln) with the polymers prior to 
gelation and found that it was retained in the gels obviating the need for covalent immobilization: 
Ln incorporated at either 75 or 250 μg·mL-1 was completely retained in hydrogels after 7 days, 
with no soluble Ln detected in the PBS supernatant (Fig. 2a). Given the large size of Ln (850 kDa), 
it was likely physically entrapped or entangled within the HA-oxime polymer chains, but may have 
also be retained by either (or both) electrostatic interactions between positively charged Ln and 
negatively charged hyaluronan-carboxylate groups[28] or reversible Schiff-base formation between 
basic lysine groups on laminin and HA-ketone/aldehyde groups.[29] The interactions between 
laminin and HA-oxime hydrogels did not alter the compressive modulus compared to HA-oxime 
only hydrogels thereby enabling the role of ECM proteins to be studied separately from mechanical 
properties (Figs. S8a).  
To investigate cell-Ln interactions, we compared cell adhesion to HA-oxime gels with or 
without Ln and found more than 2-times more T47D luminal A breast cancer cells adhered to the 
surface of hydrogels containing 75 μg·mL-1 Ln, similar to Matrigel versus controls without Ln 
(Fig. 2b). With or without Ln, breast cancer cells encapsulated in HA-oxime hydrogels were 
equally viable and evenly distributed, and the size and number of spheroids were similar (Fig. S8b-
i). Cells within the spheroids interacted with each other, as demonstrated by E-cadherin expression, 
a marker of tight junctions (Fig. 2c-d). Cells also interacted with the HA-oxime hydrogel through 
CD44, a hyaluronan receptor, and expressed β1-integrin, a Ln receptor (Fig. 2e-h). CD44 is 
essential to the growth of breast cancer cells and β1-integrin is involved in the PI3K pathway, 
which is upregulated in breast cancer and constitutes a drug target.[30] We observed some evidence 
of HIF-1α expression, a marker for either reactive oxygen species or hypoxia typically observed 
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in breast cancer tumours (Fig. 2i-j). The HIF-1α expression observed at the periphery of the 
spheroids has been observed in other cancer spheroids and likely represents reactive oxygen 
species versus hypoxia at the core because oxygen can diffuse though the ~70 µm diameter 
spheroids (Fig. S9).[31] Given the relevance of hyaluronan in breast cancer[32] and the interaction 
of cells with the HA-oxime hydrogels, we wondered whether culture in HA-oxime with or without 
laminin would impact the gene expression levels compared to those in Matrigel and conventional 
2D TCPS. 
 
Figure 2. Impact of laminin in HA-oxime hydrogels. (a) The amount of Ln retained in HA-oxime 
hydrogels crosslinked with PEGOA4 quantified by ELISA after 7 days, Ln was not detected (nd) 
from supernatant 24 h after adding PBS to HA-oxime-Ln hydrogels (n = 3 independent samples; 
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mean + standard deviation plotted, no significant differences (ns), **p<0.01, one-way ANOVA, 
Tukey’s post-hoc test). (b) Fold change in the number of breast cancer cells on HA-oxime gels 
crosslinked with PEGOA4 containing Ln versus those on Matrigel (n = 3 independent studies; 
mean + standard deviation plotted, *p<0.05; one-way ANOVA, Tukey’s post-hoc test). (c-j) 
Representative immunocytochemistry images of MDA-MB-468 cells encapsulated in HA-oxime 
hydrogels after 21 days stained for nuclei (with Hoechst, blue) and actin (with phalloidin which 
binds to F-actin, red) (c, d) E-cadherin, (e, f) CD44, (g, h) β1 integrin and (i, j) HIF-1α. 
HA-oxime Hydrogels Enable Spheroid Formation of 5 Different Breast Cancer Cell Lines 
and Patient-derived Primary Breast Cancer Cells  
When cells from 5 different breast cancer cell lines were cultured for 21 days in HA-oxime 
hydrogels +/- Ln they formed spheroids, which was not observed in 2D culture (Fig. S10). These 
cells represent 4 breast cancer subtypes with different expression profiles of estrogen receptor 
(ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2): luminal 
A MCF7 and T47D (ER+, PR+, HER2
-), luminal B BT474 (ER+, PR+, HER2+), HER2-
overexpressing MDA-MB-231-H2N (ER-, PR-, HER2+), and triple negative MDA-MB-468 (ER-, 
PR-, HER2-) cells. By examining proliferation in 2D and 3D, and between different hydrogel 
cultures, we observed that all breast cancer cell lines exhibited similar proliferation rates in HA-
oxime +/- Ln hydrogels compared to Matrigel except BT474 cells, where proliferation was 
increased in Matrigel (Fig. 3a). In addition, all cells formed spheroids of similar diameter ~100 
μm, suitable for oxygen and nutrient penetration[33] at 21 days in HA-oxime hydrogels and 
Matrigel (Fig. 3b), indicating phenotypic equivalence at minimum.  
Recent efforts to develop in vitro cancer models that recapitulate the features of human 
breast cancer for preclinical testing or personalized medicine have used poorly-defined Matrigel 
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to grow 3D tumour organoids. To test the HA-oxime hydrogel for these applications, we 
encapsulated patient-derived primary luminal B breast cancer cells in 3D therein and observed 
their survival and proliferation: the patient-derived cells grew as spheroids in the hydrogel but 
proliferated as monolayers on 2D TCPS (Fig. S11). Impressively, encapsulated primary breast 
cancer cells from a dissociated patient biopsy formed spheroids in both HA-oxime +/- Ln and 
Matrigel after 21 days of culture (Fig. 3c-f). It is possible that over the 21 days of culture within 
the 3D hydrogel, glucose and/or oxygen gradients will form and result in heterogeneity that more 
closely mimics the tumour microenvironment within the xenograft versus that of 2D TCPS. These 
results led us to perform a more extensive comparison of gene expression between the mouse 
xenografts and in vitro models in order to better understand the biological differences between 
these in vitro models. 
Gene Expression of 5 Distinct Breast Cancer Cell Lines Cultured In Vitro vs. In Vivo Growth 
as Tumour Xenografts   
In order to understand how breast cancer markers and drug-targetable pathways are 
impacted by culture platform, we benchmarked the gene expression of 5 cell lines cultured in HA-
oxime +/- Ln against orthotopic mouse xenografts in NOD SCID gamma mice and compared them 
to those in Matrigel or 2D TCPS (Fig. S12, S13). In general, the gene expression of breast cancer 
cells cultured in either HA-oxime hydrogels +/- Ln or Matrigel were more similar to that of mouse 
xenograft models than cells cultured on 2D TCPS (Fig. 3g). Several genes were differentially 
expressed compared to tumour xenografts when cultured on 2D TCPS, but not when cultured in 
HA-oxime hydrogels, including epidermal growth factor receptor (EGFR), human epidermal 
growth factor receptor 2 (ERBB2) and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic 
subunit alpha (PIK3CA) which are implicated in drug targetable pathways (Table S1). The 
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expression of both ERBB2 and EGFR can result in changes to cell phenotype and tumourigenicity, 
and may also influence response to therapy, including agents targeting these receptors directly.[34] 
In addition, patients with PIK3CA-positive breast tumours have shorter disease-free survival 
across all molecular subtypes indicating its potential as a therapeutic target.[35] Thus, these results 
further underscore the need to use representative 3D models to study breast cancer over traditional 
2D culture.  
A potential strategy for treating breast cancer beyond traditional kinase inhibitors includes 
emerging metabolic targets such as FASN, which is responsible for lipid synthesis. Currently, the 
FASN inhibitor TVB-2640 is being evaluated for the treatment of advanced breast cancer in a 
clinical trial.[36] Due to observed differences in cellular fatty acid and cholesterol content between 
2D culture and xenograft models,[37] we hypothesized that the expression of lipid metabolic genes 
would be more similar in 3D cell culture than 2D culture relative to the xenograft tumours. The 
expression of FASN, which is responsible for lipid synthesis, and ATP-binding cassette transporter 
(ABCA1), which regulates intracellular phospholipid and cholesterol homeostasis, depended upon 
both cell line and culture system. For example, luminal A MCF7 cells had similar ABCA1 and 
FASN expression between tumour xenograft and HA-oxime hydrogel culture, but an upregulated 
FASN expression when cultured on 2D TCPS or Matrigel (Fig. 3g). This shows that FASN 
expression is influenced by the ECM and that gene expression levels of xenograft tumours for 
luminal A breast cancer were recapitulated using the HA-oxime hydrogel. However, HER2-
overexpressing MDA-MB-231-H2N cells upregulated FASN and ABCA1 across all in vitro 
models, which suggests altered lipid metabolism and secretion compared to xenograft tumours. 
These differences in FASN expression were not observed for other breast cancer subtypes, which 
supports breast cancer subtype-dependent lipid metabolism in 2D.[38] Considering the similar gene 
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expression of breast cancer cells cultured in HA-oxime hydrogels and grown as xenograft tumours, 
we performed more rigorous benchmarking with a pan-cancer gene expression panel. 
 
Figure 3. Evaluation of patient-derived and 5 different breast cancer cell lines in HA-oxime +/- 
Ln versus Matrigel and 2D TCPS. (a) Cell growth at day 7 relative to day 1 (n = 3; mean + s.d. 
plotted, *p<0.05, one-way ANOVA, Tukey’s post-hoc test). (b) Tumour spheroid diameter after 
21 days of culture for cells embedded in HA-oxime, HA-oxime-Ln or Matrigel (n = 3; mean + s.d. 
plotted, *p<0.05, one-way ANOVA, Tukey’s post-hoc test). No spheroids were formed on 2D 
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TCPS. (c-f) Representative images of primary, patient breast cancer cells after 21 days of culture 
in (c) HA-oxime, (d) HA-oxime + Ln, (e) Matrigel or (f) 2D TCPS. Cells stained with phalloidin 
(binds to F-actin, shown in green) and Hoechst (nuclei, shown in blue); scale bar represents 50 
μm. (g) Heat map gene expression of MCF7, T47D, BT474, MDA-MB-231-H2N, and MDA-MB-
468 cells encapsulated in HA-oxime, HA-oxime-Ln, Matrigel, or cultured on 2D TCPS after 21 
days and compared to the respective mouse xenograft tumours. Expression reported as the Log2 
ratio from qPCR with black indicating the greatest similarity (n = 3-5 independent studies; mean 
plotted). 
Pan-Cancer Gene Expression Benchmarks In Vitro Breast Cancer Models  
In order to better understand the predictive powers of 3D in vitro culture of breast cancer 
cells, we benchmarked 3 distinct cell lines, representing 3 different breast cancer subtypes, to 
tumour xenografts: luminal B (BT474); HER2-overexpressing (MDA-MB-231-H2N); and triple 
negative (MDA-MB-468). We cultured cells in 3D in HA-oxime, Matrigel or in 2D on TCPS and 
compared the gene expression panel of 730 cancer-related genes. Relative to tumour xenografts, 
we found that luminal B, BT474 cells had the fewest number of differentially expressed genes 
when cultured in HA-oxime gels (24 downregulated and 27 upregulated of 730 genes) compared 
to those cultured in Matrigel (63 downregulated and 135 upregulated) and on 2D TCPS (60 
downregulated, 45 upregulated) (Fig. 4a, b, Table S2). Surprisingly, there were more differences 
when cells were cultured in Matrigel than on 2D TCPS relative to xenografts, which both reflects 
the unsuitability of Matrigel and demonstrates that 3D culture alone is insufficient for predictive 
drug screening.   
We analyzed 12 pathways and driver genes by gene set variation analysis and found that 
BT474 cells cultured in Matrigel altered the expression of several pathways including JAK-STAT 
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and MAPK versus tumour xenografts whereas cells cultured in HA-oxime gels did not (Fig. 4c). 
This further motivates the use of representative, benchmarked 3D in vitro models, such as the HA-
oxime hydrogel, to recapitulate gene expression and to evaluate new drug candidates against JAK-
STAT and MAPK.[39]  
Comparing the gene expression of MDA-MB-231-H2N tumours to 3D hydrogels and 2D 
culture, we found that fewer genes were differentially expressed when cells were grown in HA-
oxime gels (16 downregulated, 12 upregulated) versus both Matrigel (28 downregulated, 21 
upregulated) and 2D TCPS (33 downregulated, 29 upregulated) (Fig. 4d, e, Table S3). Altered 
gene expression of a therapeutic target in cells used in an in vitro drug screen would generate 
misleading data. Differences in the JAK-STAT pathway were identified between cells cultured in 
HA-oxime, Matrigel or 2D TCPS relative to the tumour xenografts after analyzing the pathways 
regulating cell survival and cell fate between the in vitro models and tumour xenografts of MDA-
MB-231-H2N cells (Fig. 4f). 
When triple-negative breast cancer (TNBC) MDA-MB-468 cells were cultured in HA-
oxime gels, Matrigel or 2D TCPS, a similar number of genes were downregulated compared to the 
xenograft tumours (125, 134 and 122, respectively) while the number of upregulated genes was 
higher in 2D TCPS (94) versus HA-oxime and Matrigel (60 and 54 genes, respectively) (Fig. 4g, 
h, Table S4). Subsequent analysis of affected pathways revealed that the hedgehog pathway was 
altered when cultured in HA-oxime, Matrigel or 2D TCPS relative to the tumour xenografts (Fig. 
4i). Since only 30% of triple-negative breast cancers involve paracrine hedgehog (Hh) signalling, 
which has been studied in the context of cancer-associated fibroblasts, co-culture models may be 
required to target this pathway.[40] 
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Our gene expression pathway analyses show that the JAK-STAT pathway was altered in 
both HER2+ BT474 and MDA-MB-231-H2N cell lines when cultured in Matrigel or on 2D TCPS 
relative to xenograft and HA-oxime. This underlines the need to evaluate drugs targeting specific 
pathways on validated models. Remarkably, while Matrigel is thought to be the gold standard for 
in vitro culture, it has not been benchmarked previously and our data clearly demonstrate that it is 
sub-optimal. Overall, HA-oxime gels were the most similar to xenografts, with only 294 
differentially expressed genes vs. 434 for Matrigel and 371 for 2D TCPS (Figure 4j, Fig. S14). 
The number of differentially expressed genes for the same cell lines was similar between HA-
oxime and HA-oxime-Ln hydrogels (294 versus 308 genes, respectively) compared to the 
xenograft tumours (Fig. S14b). Thus, 3D culture reduces, but does not eliminate, differences in 
gene expression between 2D culture and xenografts. 3D culture in HA-oxime better emulates the 
gene expression profile of xenografts than culture in Matrigel. 
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Figure 4. Comparison of in vitro gene expression and pathway analysis for three breast cancer cell 
lines relative to tumour xenografts in mice. (a, b) Venn Diagrams depicting the number genes 
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differentially expressed by BT474 cells cultured in vitro compared to xenografts. (c) Pathway 
specific expression correlation values and p-values by gene set variation analysis of BT474 cells 
cultured in vitro versus tumour xenografts. Altered pathways in cells cultured in vitro are shown 
above the dashed line. (d, e) Venn diagrams depicting the number genes differentially expressed 
by MDA-MB-231-H2N cells cultured in vitro compared to xenografts. (f) Pathway specific 
expression correlation values and p-values by gene set variation analysis of MDA-MB-231-H2N 
cells cultured in vitro versus tumour xenografts. Altered pathways in cells cultured in vitro are 
shown above the dashed line. (g, h) Venn Diagrams depicting the number genes differentially 
expressed by MDA-MB-468 cells cultured in vitro compared to xenografts. (i) Pathway specific 
expression correlation values and p-values by gene set variation analysis of MDA-MB-468 cells 
cultured in vitro versus tumour xenografts. Altered pathways in cells cultured in vitro are shown 
above the dashed line. Pathway specific expression correlation values and p-values by gene set 
variation analysis versus tumour xenografts. (j) Summary of all observed differentially expressed 
genes after culture in HA-oxime, Matrigel, or 2D TCPS versus mouse xenograft tumours for 
BT474, MDA-MB-231-H2N, and MDA-MB-468 cells (n = 3 except for BT474 cells grown in 
Matrigel where n = 4). 
Evaluating Differences in Drug Response Between 2D and 3D Models 
To understand if these differences in gene expression could influence cell response in drug 
screening, we specifically chose drugs that target pathways differentially expressed between 
xenograft and in vitro culture in Matrigel and 2D TCPS and that were not differentially expressed 
in HA-oxime (Table S4, S5). We tested a series of drugs that target the MAPK (such as Rac 
signaling) and JAK-STAT pathways of BT474 cells grown in HA-oxime vs. Matrigel and 2D 
TCPS.  
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BT474 cells treated with EHT-1864 (Rac inhibitor, targeting the MAPK/ERK pathway) 
were more responsive when cultured in HA-oxime than in Matrigel (Fig. 5a, Fig. S15). In addition, 
BT474 cells cultured in HA-oxime were more responsive to AZD6482 (PI3Kβ inhibitor involved 
in the JAK-STAT pathway) than those cultured in Matrigel or on 2D TCPS (Fig. 5b). To gain 
biological insight into the mechanism underlying the observed differences in drug responsiveness, 
we quantified the number of genes involved in MAPK and JAK-STAT signaling pathways with 
differential expression levels relative to tumour xenografts: cells cultured in HA-oxime had fewer 
differentially expressed genes (14 for MAPK and 4 for JAK-STAT) compared to cells cultured in 
both Matrigel (43 for MAPK and 29 for JAK-STAT) and on 2D TCPS (23 for MAPK and 10 for 
JAK-STAT) (Fig. 5c-e, red circles for MAPK and green circles for JAK-STAT). Together these 
results demonstrate the superiority of HA-oxime over Matrigel and 2D TCPS in drug screening 
where specific pathways are targeted. 
Interestingly, cells cultured in HA-oxime were over tenfold more sensitive to maritoclax 
(Fig. S15c), an Mcl-1 inhibitor which prevents the normal anti-apoptotic signaling by Mcl-1 on 
the mitochondria resulting in apoptosis, with an IC50 of 0.59 μM than those cultured in 2D TCPS 
with IC50 of 5.5 μM (Fig. 5f). Moreover, primary, human patient tumour luminal B breast cancer 
cells were significantly more sensitive to maritoclax when cultured in 3D HA-oxime than those 
cultured on 2D TCPS as well, demonstrating both the potential of the HA-oxime hydrogels in 
personalized medicine and the importance of culture conditions in drug screening (Fig. S16). 
Maritoclax targets the apoptosis pathway as an inhibitor of anti-apoptotic protein Mcl-1 on the 
mitochondria. Regulators of this apoptosis pathway, BAD (pro-apoptotic) and BCL2 (anti-
apoptotic), had decreased levels in BT474 cells cultured on 2D TCPS relative to 3D culture, which 
explains the observed differences in drug response (Fig. 5g).  
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We highlight the results of the in vitro drug screening performed with BT474 cells where 
IC50 values differed between HA-oxime, Matrigel and 2D TCPS (Fig. 5h). Since the decision to 
test drugs in animal models of disease is often based on in vitro screening, maritoclax, EHT-1864 
and AZD6482 would have been excluded based on culture in Matrigel and/or 2D TCPS, thereby 
reflecting the importance of culture in a representative matrix, such as HA-oxime. The differences 
between 2D and 3D culture of breast cancer cells are significant in terms of gene expression and 
drug response. While cell response did not always differ between the 3 culture conditions (as 
shown with ZSTK474 and afatinib, Fig. S15), to ensure comprehensive screening, a validated, 
representative system, like HA-oxime, is required. 
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Figure 5. Targeting pathways in BT474 breast cancer cells cultured in vitro with drugs. (a, b) IC50 
values for BT474 cells cultured in vitro treated with (a) EHT 1864 targeting the MAPK pathway 
or (b) AZD6482 targeting the JAK-STAT pathway (n = 3 independent experiments; mean + 
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standard deviation plotted, *p<0.05, **p<0.01, by one-way ANOVA, Tukey’s post-hoc test). (c-
d) Volcano plots of differentially expressed genes involved in MAPK signalling (red), JAK-STAT 
signalling (green), both pathways (yellow), other (blue) and similarly expressed (white) when 
cultured in (c) HA-oxime, (d) Matrigel or on (e) 2D TCPS versus tumour xenografts. (f) IC50 
values for BT474 and patient derived breast cancer cells cultured in vitro treated with maritoclax 
targeting the apoptosis pathway (n = 3 independent experiments; mean + standard deviation 
plotted, **p<0.01, ***p<0.001 by one-way ANOVA, Tukey’s post-hoc test). (g) Gene expression 
counts of apoptosis signalling genes BAX, BAD and BCL2 for BT474 cells cultured in vitro or as 
tumour xenografts. (h) Summary of observed statistical differences in IC50 values from drug 
screening with EHT 1864 (which targets MAPK), AZD6482 (which targets JAK-STAT) and 
maritoclax (which targets apoptosis) with BT474 cells cultured in HA-oxime, Matrigel or on 2D 
TCPS. IC50 values that were statistically different depending on culture platform are shown in red 
while those which were not statistically different are shown in green. 
To gain insight into the broader utility of the HA-oxime hydrogels with other cell types, 
we investigated the efficacy of erlotinib, an EGFR inhibitor, against TNBC MDA-MB-468 cells. 
Cells that were grown on 2D TCPS, in Matrigel or HA-oxime for 21 days and treated with erlotinib 
for 7 days had a significantly higher IC50 of 37.6 μM (p<0.01) compared to those cultured in 3D 
of ~4.5 μM (Fig. S17). MDA-MB-468 cells cultured on 2D were less sensitive to erlotinib than 
other cancer cell lines, despite its established effectiveness in breast cancer xenografts in mice,[41] 
further highlighting the importance of relevant screening assays. 
Conclusions  
3D cell culture has several features which make it attractive for drug screening, yet is limited by 
the use of Matrigel, which does not faithfully recapitulate the gene expression profile of the tumour 
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xenograft and is chemically ill-defined. The newly synthesized HA-oxime hydrogels have 
controlled and tunable gelation, mechanical properties, and chemical properties that mimic the 
breast ECM, which are not possible with 2D TCPS and limited with Matrigel. By benchmarking 
to the in vivo gold standard for the first time, we demonstrate that breast cancer cells grown in HA-
oxime hydrogels most closely resemble orthotopic xenografts in terms of gene expression profiles 
of 3 distinct breast cancer subtypes. This impacts the value of in vitro drug screening. Formulating 
the HA-oxime hydrogels with laminin did not reduce the number of differentially expressed genes 
expressed by the breast cancer spheroids compared to the tumour xenografts. Our analysis of 
canonical signaling pathways using the gene expression data suggest breast cancer subtype-
dependant changes to gene expression with culture platform. We demonstrated the ability to grow 
patient-derived breast cancer cells in HA-oxime hydrogels and thereby identify relevant drug 
candidates. Thus, hyaluronan-oxime hydrogels bridge the gap between 2D drug screening in vitro 
and in vivo mouse xenograft models, opening the door to personalized medicine and more 
predictive drug screening. To take full advantage of this opportunity, scale up and simultaneous 
screening of multiple drugs is required. This well-defined hydrogel platform opens up the 
possibility for more complex 3D models with co-culture of multiple cell types, thereby better 
emulating the complexity of tumours. 
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